A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

Author： Massarweh Suleiman  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.129, Iss.3, 2011-10, pp. : 819-827

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

By Bernsdorf Mogens  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 463-470

Springer Publishing Company

Access to resources Recommend Favorite

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

By Carlson Robert  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1049-1056

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

By Kurosumi Masafumi   Takatsuka Yuichi   Watanabe Toru   Imoto Shigeru   Inaji Hideo   Tsuda Hitoshi   Akiyama Futoshi   Sakamoto Goi   Ikeda Tadashi   Noguchi Shinzaburo  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 6, 2008-06 ,pp. : 715-722

Springer Publishing Company

Access to resources Recommend Favorite

Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer

By Bernsdorf Mogens   Balslev Eva   Lykkesfeldt Anne   Kroman Niels   Harder Eva   Maase Hans   Jakobsen Erik   Grabau Dorthe   Ejlertsen Bent  

Breast Cancer Research and Treatment, Vol. 128, Iss. 1, 2011-07 ,pp. : 165-170

Springer Publishing Company

Access to resources Recommend Favorite